Penumbra, Inc. (PEN)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$321.11-0.42%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · PEN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | 1,560.3 | 1,403.7 | 1,194.6 | 1,058.5 | 847.1 | 747.6 | 560.4 | 547.4 | 444.9 | 333.8 | 263.3 | 186.1 |
| Total Revenues | 1,560.3 | 1,403.7 | 1,194.6 | 1,058.5 | 847.1 | 747.6 | 560.4 | 547.4 | 444.9 | 333.8 | 263.3 | 186.1 |
| Cost of Revenues | 499.5 | 461.2 | 439.6 | 375.9 | 311.9 | 272.2 | 222.2 | 175.4 | 152.4 | 116.6 | 92.5 | 62.0 |
| Gross Profit | 1,060.8 | 942.4 | 755.0 | 682.6 | 535.2 | 475.4 | 338.2 | 372.0 | 292.5 | 217.1 | 170.8 | 124.1 |
| Operating Expenses & Income | ||||||||||||
| Selling, General & Admin | 776.6 | 663.4 | 574.0 | 506.5 | 449.7 | 378.3 | 287.1 | 272.7 | 226.4 | 184.3 | 148.3 | 101.9 |
| R&D Expenses | — | — | — | — | — | — | — | — | 36.2 | 31.7 | 23.9 | 18.0 |
| Operating Income | 189.2 | 189.2 | 9.3 | 73.6 | 6.1 | (7.5) | (38.9) | 47.5 | (0.9) | 1.2 | (1.4) | 4.2 |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | — | 1.3 | 1.4 | 1.7 | 1.7 | 1.9 | — | — | — | — | — | — |
| Interest & Investment Income | 21.5 | 16.3 | 13.7 | 6.8 | 1.9 | 2.9 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (5.1) | (0.1) | (0.9) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 18.6 | 15.9 | 11.6 | 6.1 | (2.2) | (3.0) | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 207.8 | 205.1 | 20.9 | 79.7 | 3.9 | (10.5) | (38.0) | 50.1 | 1.6 | 2.5 | (0.9) | 4.0 |
| Income Tax Expense | 50.8 | 27.4 | 6.9 | (11.3) | 5.9 | (13.1) | (18.8) | 3.1 | (4.4) | (3.6) | (15.7) | 1.7 |
| Earnings from Continuing Operations | — | — | — | — | — | — | (19.3) | 47.0 | 6.0 | 6.1 | — | — |
| Net Income | ||||||||||||
| Minority Interest | — | — | — | 0.0 | 0.0 | (2.7) | (3.6) | (1.5) | (3.7) | — | — | — |
| Net Income | 157.0 | 177.7 | 14.0 | 91.0 | (2.0) | 5.3 | (15.7) | 48.5 | 6.6 | 4.7 | 14.8 | 2.4 |
| Per Share | ||||||||||||
| Basic EPS | 3.98 | 4.57 | 0.36 | 2.37 | (0.05) | 0.14 | (0.44) | 1.39 | 0.19 | 0.14 | 0.49 | 0.09 |
| Diluted EPS | 3.96 | 4.52 | 0.36 | 2.32 | (0.05) | 0.14 | (0.44) | 1.34 | 0.18 | 0.13 | 0.44 | 0.08 |
| Revenue per Share | 39.38 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 39.4 | 38.9 | 38.6 | 38.4 | 37.8 | 36.8 | 35.8 | 34.8 | 34.1 | 33.0 | 30.5 | 12.0 |
| Diluted Weighted Avg Shares | 39.6 | 39.3 | 39.3 | 39.2 | 37.8 | 37.9 | 35.8 | 36.3 | 36.1 | 35.3 | 33.5 | 14.2 |
| Supplemental | ||||||||||||
| EBITDA | — | 206.7 | 33.0 | 100.8 | 30.4 | 8.9 | (26.1) | 55.6 | 5.3 | 4.9 | 0.9 | 5.9 |
| EBIT | 189.2 | 189.2 | 9.3 | 73.6 | 6.1 | (7.5) | (38.9) | 47.5 | (0.9) | 1.2 | (1.4) | 4.2 |
| Effective Tax Rate | 24.4% | — | — | -14.2% | 151.4% | 125.0% | 49.3% | 6.2% | -273.8% | -145.8% | 1804.7% | 41.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.